Abstract:<span class="paragraphSection">BackgroundTriple Negative Breast Cancer (TNBC) is the most belligerent subtype of BC. Yet, it is considered the best candidate for immunotherapy. As TNBC microenvironment is rich in CD8+ T lymphocytes (CTLs) and Natural Killer cells (NKs), the main key players in BC immune surveillance. During the antitumor immune-response, CTLs and NKs recognize and eliminate BC cells through an array of activating receptors expressed on their surface. CD226 and NKG2D are among the most vital activating receptors present on CTLs, NKs and NKT cells. The rate limiting step in tumor eradication is the binding of the aforementioned receptors to their respective ligands (Major histocompatibility complex class I chain-related proteins A and B (MICA/B) and CD155). Unfortunately, recent studies highlight the extensive shedding of MICA/B and CD155 in TNBC patients. Lately, our group nominated miR-486-5p as an immuno-activating miRNA. However, its impact on TNBC immune ligands has never been investigated. Therefore, our aim is to investigate the impact of miR-486-5p on MICA/B and CD155 in an attempt to alleviate the immune-suppressive nature of TNBC cells.MethodsTNBC patients (n = 25) were recruited. Bioinformatics were performed to verify the binding of miR-486-5p to MICA/B and CD155. MDA-MB-231 and MCF7 cells were cultured and transfected with miR-486-5p oligonucleotides. Total RNA was extracted and quantified by qRT-PCR. Cellular viability and clonogenicity were performed using MTT and colony forming assays, respectively.ResultsTNBC patients showed a significant down-regulatory pattern of miR-486-5p, MICA, MICB and CD155 compared to its normal counterparts. In a similar pattern, miR-486-5p, MICA, MICB and CD155 were found to be markedly down-regulated in MDA-MB-231 cells. In-silico results proved that miR-486-5p potentially targets MICA, MICB and CD155. Ectopic expression of miR-486-5p (>1000 folds) resulted in a marked induction of MICA/B (2 folds) and CD155 (5 folds) thus potentiating NKs and CTLs cytotoxicity. Functionally, miR-486-5p mimics resulted in a significant repression of TNBC cellular viability and colony forming ability.ConclusionmiR-486-5p is an immunomodulatory tumor suppressor miRNA acts by alleviating the immunesuppressive profile of TNBC cells.Legal entity responsible for the studyGerman University in Cairo.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.</span>

Pterostilbene upregulates MICA/B via the PI3K/AKT signaling pathway to enhance the capability of natural killer cells to kill cervical cancer cells

Elucidating the Molecular Mechanisms of Pterostilbene Against Cervical Cancer Through an Integrated Bioinformatics and Network Pharmacology Approach

Pterostilbene Simultaneously Induces Apoptosis, Cell Cycle Arrest and Cyto-Protective Autophagy in Breast Cancer Cells.

Tetramethypyrazine inhibits renal cell carcinoma cells through inhibition of NKG2D signaling pathways

The clinical and biological significance of MICA in clear cell renal cell carcinoma patients

Pterostilbene modulates the suppression of multidrug resistance protein 1 and triggers autophagic and apoptotic mechanisms in cisplatin-resistant human oral cancer CAR cells via AKT signaling

Midkine Upregulates Mica/B Expression in Human Gastric Cancer Cells and Decreases Natural Killer Cell Cytotoxicity

Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer

Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway

Pterostilbene in the treatment of inflammatory and oncological diseases

Resveratrol Promotes MICA/B Expression and Natural Killer Cell Lysis of Breast Cancer Cells by Suppressing C-Myc/mir-17 Pathway.

Sodium Butyrate Upregulates Expression of NKG2D Ligand MICA/B in HeLa and HepG2 Cell Lines and Increases Their Susceptibility to NK Lysis

Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms

Splicing Factor PTBP1 Silencing Induces Apoptosis of Human Cervical Cancer Cells via PI3K/AKT Pathway and Autophagy

A new quercetin glycoside enhances TNBC immunological profile through TP53/miR-155/MICA/ULBP2

Targeted MIP-3β plasmid nanoparticles induce dendritic cell maturation and inhibit M2 macrophage polarisation to suppress cancer growth

M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway

miR-486-5p Counteracts the Shedding of MICA/B and CD155 Immune-Ligands in TNBC Patients

Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer

M1 macrophage-membrane-cloaked paclitaxel/β-elemene nanoparticles targeting cervical cancer for enhanced therapy

Reversing Immune Suppression and Potentiating Photothermal Immunotherapy Via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres